Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
(CSE:
BNXT
)
0.6000
+0.0500 (+9.09%)
Streaming Delayed Price
Updated: 3:59 PM EST, Feb 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BNXT
< Previous
1
2
3
Next >
BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization
May 05, 2025
Via
ACCESS Newswire
BioNxt Solutions Prepares for Human Bioequivalence Study For MS
April 23, 2025
Via
ACCESS Newswire
Clarification of Promotional Activities
February 21, 2025
Via
ACCESS Newswire
BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion
February 19, 2025
Via
ACCESS Newswire
BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
January 21, 2025
Via
ACCESS Newswire
BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement
October 27, 2023
Via
ACCESSWIRE
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
December 19, 2024
Via
ACCESSWIRE
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
December 09, 2024
Via
ACCESSWIRE
BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
December 02, 2024
Via
ACCESSWIRE
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
November 25, 2024
Via
ACCESSWIRE
Terry Lynch Joins BioNxt as Capital Markets Advisor
October 06, 2024
Via
ACCESSWIRE
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
September 26, 2024
Via
ACCESSWIRE
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
September 09, 2024
Via
ACCESSWIRE
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
August 14, 2024
Via
ACCESSWIRE
BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
July 16, 2024
Via
ACCESSWIRE
BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization
July 08, 2024
Via
ACCESSWIRE
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
March 17, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study
March 14, 2024
Via
Investor Brand Network
Topics
Intellectual Property
BioNxt Reports Successful Results From ODF Cladribine PK Study
March 12, 2024
Via
ACCESSWIRE
BioNxt Reports Successful Results From ODF Cladribine Toxicity Study
February 07, 2024
Via
ACCESSWIRE
BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
December 12, 2023
Via
ACCESSWIRE
BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
November 20, 2023
Via
ACCESSWIRE
BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
November 15, 2023
Via
ACCESSWIRE
BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
November 13, 2023
Via
ACCESSWIRE
BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease
August 02, 2023
Via
ACCESSWIRE
BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s Disease
May 15, 2023
Via
ACCESSWIRE
BioNxt Successfully Completes Pilot Study for Contract Development Customer
May 09, 2023
Via
ACCESSWIRE
BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Company
April 24, 2023
Via
ACCESSWIRE
BioNxt Acquires Commercial Coating and Cutting Equipment to Build Out European Commercial Manufacturing Capacity
April 17, 2023
Via
ACCESSWIRE
BioNxt Solutions Acquires Novel Precision Drug Coating and Delivery Technology
March 07, 2023
Via
ACCESSWIRE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
